TOTAL POWER OF HEART RATE VARIABILITY AND CLINICAL EFFECIANCY OF AMLODIPIN IN ADVANCED PATIENTS WITH ARTERIAL HYPERTENSION

  • L.V. Аnufrieva
  • M.I. Yabluchansky
  • О.Yu. Bychkova

Анотація

Twenty patients (average age 63,25±5,4 years) with arterial hypertension I-III stage were outclinic observed. Estimated parameters were levels systolic and diastolic blood pressure, frequency of heart beats, general index of quality of life (GIQL) and parameters of a spectral analysis heart rate variability (HRV) before treatment, on a background of therapy and in acute pharmacological test (APT) with amlodipin. Depending on reaction of total power (ТР) of a spectrum HRV in APT all patients were divided into 2 groups: with positive and negative reaction ТР. Irrespective of a type of reaction ТР HRV in APT and on a background of therapy at all patients were marked authentic rising GIQL and high clinical efficiency amlodipin. The most expressed and the early hypotensive effect were marked in group of the patients with negative reaction ТР HRV.

Завантаження

##plugins.generic.usageStats.noStats##

Посилання

1. Pahor M., Psaty B.M., Alderman M.N. et al. // Lancet. 2000. Vol. 356. P. 1949-1954.

2. Сіренко Ю.М., Радченко Г.Д., та інш. // Вісник дніпропетровського університету. 2000. вып. 2. С.21-23.

3. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertension. 2003. P. 1011-1053.

4. Преображенский Д.В., Сидоренко Б.А., Шабаева Е.Н. // Кардиология. 1998. № 2. С. 66-72.

5. Cushman WC, Ford CE, Cutler JA, et al. // J Clin Hypertens. 2002. № 4. P. 1-12.

6. Яблучанский Н.И., Мартыненко А.В, Исаева А.С. Основы практического применения неинвазив-ной технологии исследования регуляторных систем человека. Харьков: «Основа». 2000. 87 с.

7. Lindholm L.H., Hansson L. // Blood Press. 1996. Vol.5. P.300-304.

8. Коркушко О.В., Саркисов К.Г., Забияка Л.К. и др. // Укр. кардіол. журн. 2001. №4. С. 43-48.

9. CAMELOT: Comparison of amlodipin versus enalapril to limit occurrences of thrombosis. Data on file. -N.Y.: Pfizer Inc. 1999. 386 p.

10. Arteaga W., Windle J.// Archives of Internal Medicine. 1995. №.155. Р. 2086-2091.

11. Standards of measurment, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, (Membership of the Task Forcelisted in the Appendix) // Eur Heart J. 1996. № 17. P. 354-381.
Як цитувати
АnufrievaL., Yabluchansky, M., & BychkovaО. (1). TOTAL POWER OF HEART RATE VARIABILITY AND CLINICAL EFFECIANCY OF AMLODIPIN IN ADVANCED PATIENTS WITH ARTERIAL HYPERTENSION. Вісник Харківського національного університету імені В. Н. Каразіна. Серія «Медицина», (6), 36-41. вилучено із https://periodicals.karazin.ua/medicine/article/view/7294
Номер
Розділ
Clinical Research